Login
$HROW
$29.20 -$0.92 (3.05%) Live

$HROW SEC Filings

Filed On Filing
16 Nov 2026 8-K: Regulation FD Disclosure

Registrant’s telephone number, including area code: (615) 733-4730

12 Nov 2026 SCHEDULE 13G/A
09 Nov 2026 10-Q
09 Nov 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

The second-half ramp we anticipated materialized as Harrow reported record third quarter revenue of $99.3 million, up 41% sequentially and 39% year over year. Branded products led the way, providing $83.5 million in revenue, up 62% year ...

06 Nov 2026 SCHEDULE 13G/A
27 Oct 2026 SCHEDULE 13G/A
05 Oct 2026 8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +1 more

First and Only FDA-Approved Nasal Spray for Dry Eye Disease Adds a Differentiated, Drop-Free Treatment Option to Harrow’s Growing Ocular Surface Franchise

04 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation

Effective September 4, 2026, Randall E. Pollard ceased serving as Chief Accounting Officer and principal accounting officer of Harrow, Inc. (the “Company”).

21 Aug 2026 144
17 Aug 2026 Form 4: Shojaei Amir, CHIEF SCIENTIFIC OFFICER

Received 11,250 shares by exercise or conversion ($405K) · Sold 11,250 shares ($450K)

10 Aug 2026 10-Q
10 Aug 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

The first half of 2026 was about driving demand and fine-tuning business rules; the second half is about converting growing demand into revenue and profits. The balance of this Letter to Stockholders describes why I believe we are set up...

06 Aug 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

NASHVILLE, Tenn., August 6, 2026 – Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into a definitive agreement to acquire TYRVAYA® (varenicline so...

31 Jul 2026 SCHEDULE 13G/A
22 Jun 2026 Form 4: Sternberg Perry J., Director

Granted 5,248 RSU

22 Jun 2026 Form 4: Silvernail Lauren P, Director

Granted 5,248 RSU

22 Jun 2026 Form 4: Graves Adrienne L, Director

Granted 5,248 RSU

22 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 18, 2026, Harrow, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The number of shares of common stock entitled to vote at the Annual Meeting was 37,273,420. The number of shares of commo...

03 Jun 2026 8-K: Regulation FD Disclosure

Attached as Exhibit 99.1 to this Current Report on Form 8-K is a corporate presentation of Harrow, Inc. (the “Company”), dated June 2026, which may be used from time to time by the Company’s management at investor conferences and in meet...

19 May 2026 Form 4: Graves Adrienne L, Director

Bought 1,000 shares ($31.1K)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support